Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

This article provides billing and coding instructions for Next-Generation Sequencing lab-developed tests for myeloid malignancies (per LCD L38047). Claims must report the appropriate CPT and ICD-10-CM codes, use exactly 1 unit of service, and include the correct DEX Z-Code adjacent to the CPT code in the specified comment/narrative fields for Part A and Part B (with strict formatting requirements for SV101-7).

"Next-generation sequencing (NGS) lab-developed tests (LDTs) for myeloid malignancies and suspected myeloid malignancies are addressed by this billing/coding guidance in conjunction with LCD L38047."

Sign up to see full coverage criteria, indications, and limitations.